Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer

References

• Glynne-Jones R, Wyrwicz L, Tiret E, et al. on behalf of the ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22–iv40.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. on behalf of the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 (Suppl 3):iii1–9.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 (Suppl 3):iii10–20.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl_5):v38–v49.
   PubMed Web of Science ®Google Scholar
• Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl_5):v50–v57.
   PubMed Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl_5):v28–v37.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 (Suppl 5):v56–68.
   PubMed Web of Science ®Google Scholar
• Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2012;136(3):777–788.
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JA, Kaufmann M, Siedentopf F, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist. 2012;17(4):476–484.
   PubMed Web of Science ®Google Scholar
• Gregoire V, Lefebvre JL, Licitra L, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Med Oncol. 2010;21 (Suppl 5):v184–6.
   Google Scholar
• Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–984.
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202.
   PubMed Web of Science ®Google Scholar
• Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.
   Web of Science ®Google Scholar
• Sorrentino MF, Kim J, Foderaro AE, et al. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19(5):453–458.
   PubMed Web of Science ®Google Scholar
• Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487–493.
   PubMed Web of Science ®Google Scholar
• Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2007;134(1):75–82.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002;13(3):484–485.
   PubMed Web of Science ®Google Scholar
• Gaveau T, Banzet P, Marneffe H, et al. Cardiovascular disorders in the course of antimitotic infusions at high doses. 30 clinical cases. Anesth Analg. 1969;26(3):311–327.
   Google Scholar
• Polk A, Vistisen K, Vaage-Nilsen M, et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15(1):47.
   PubMed Web of Science ®Google Scholar
• Khan MA, Masood N, Husain N, et al. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc. 2012;62(5):430–434.
   PubMed Web of Science ®Google Scholar
• Koca D, Salman T, Unek I, et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy. 2011;57 (5):381–387.
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta G, Clerici M, et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori. 1982;68(6):505–510.
   PubMed Web of Science ®Google Scholar
• Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–736.
   PubMed Web of Science ®Google Scholar
• Jensen SA, Hasbak P, Mortensen J, et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. JCO. 2010;28(36):5280–5286.
   PubMed Web of Science ®Google Scholar
• Meydan N, Kundak I, Yavuzsen T, et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol. 2005;35(5):265–270.
   PubMed Web of Science ®Google Scholar
• Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41(11):1542–1546.
   PubMed Web of Science ®Google Scholar
• Wacker A, Lersch C, Scherpinski U, et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology. 2003;65(2):108–112.
   PubMed Web of Science ®Google Scholar
• Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. JCO. 1989;7(4):509–514.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. 5-Fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer. Clin Colorectal Cancer. 2019;18(1):58–63.
   PubMed Web of Science ®Google Scholar
• Kwakman JJ, Simkens LH, Mol L, et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer. 2017;76:93–99.
   PubMed Web of Science ®Google Scholar
• Polk A, Shahmarvand N, Vistisen K, et al. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open. 2016;6(10):e012798.
   PubMed Web of Science ®Google Scholar
• Lestuzzi C, Vaccher E, Talamini R, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Med Oncol/ESMO. 2014;25(5):1059–1064.
   Google Scholar
• Smoragiewicz M, Javaheri KR, Yin Y, et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer. 2014;45(4):460–465.
   PubMedGoogle Scholar
• Aspinall SL, Good CB, Zhao X, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015;15(1):62.
   PubMed Web of Science ®Google Scholar
• Mochinaga S, Okahashi T, Koga S, et al. Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer. Oncol Res. 2011;19(10):511–518.
   PubMed Web of Science ®Google Scholar
• Munker S, Gerken M, Fest P, et al. Chemotherapy for metastatic colon cancer: no effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018;18(1):455.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Sara J, Lobo R, et al. Bolus 5-fluorouracil (5-FU) in combination with oxaliplatin is safe and well tolerated in patients who experienced coronary vasospasm with infusional 5-FU or capecitabine. Clin Colorectal Cancer. 2019;18:52–57.
   PubMed Web of Science ®Google Scholar
• Deboever G, Hiltrop N, Cool M, et al. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer. 2013;12(1):8–14.
   PubMed Web of Science ®Google Scholar
• Lemaire L, Malet-Martino MC, de FM, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer. 1992;66(1):119–127.
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Haruno A, Yoshimura Y, et al. Effect of coadministration of uracil on the toxicity of tegafur. J Pharm Sci. 1984;73(2):212–214.
   PubMed Web of Science ®Google Scholar
• Kwakman JJM, Baars A, van Zweeden AA, et al. Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. Eur J Cancer. 2017;81:130–134.
   PubMed Web of Science ®Google Scholar
• Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 2014;25(1):117–121.
   PubMed Web of Science ®Google Scholar
• Cunningham D, the "Tomudex" Colorectal Cancer Study Group, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. “Tomudex” Colorectal Cancer Study Group. Ann Oncol. 1996;7(9):961–965.
   PubMed Web of Science ®Google Scholar